At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 24 enrolled
Drug / intervention
Vilazodone +2 moredrug
Likely dose
Vilazodone 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Vilazodone for Corticosteroid-Induced Memory Impairment
University of Texas Southwestern Medical Center·interventional·Posted Apr 10, 2013·Updated Apr 11, 2019
In Brief
A Phase 2 clinical trial evaluating Vilazodone, Placebo, and 1 other intervention for Memory Impairment. Completed, enrolled 24 participants across 1 site.
Detailed Summary
The purpose of this study is to examine whether vilazodone attenuates the memory and mood effects of corticosteroids on the human hippocampus in 24 healthy controls.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMemory Impairment
CountriesUnited States
CollaboratorsForest Laboratories
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2012
First PostedApr 2013
Primary CompletionApr 2014
TodayJul 2026
First PostedApr 10, 2013
Enrollment StartDec 1, 2012
Primary CompletionApr 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 13.2 years ago
Interventions
Vilazodonedrug
Participants will be randomized to either vilazodone or placebo titrated as follows: 10 mg x 7 days, 20 mg x 7 days and 40 mg x 5 days.
Placebodrug
Hydrocortisonedrug
Participants receive 160 mg x 4 days after vilazodone or placebo pre-treatment